LUZHU BIOTECH-B (02480.HK): RSV vaccine cleared for China trial
- RSV is a common respiratory pathogen that can develop into severe conditions such as bronchiolitis and pneumonia; China currently has no RSV-specific therapeutic drug, with clinical care mainly supportive.
- The clinical trial approval lays a foundation for the Group's development of subsequent recombinant protein vaccine candidates.
NewTimeSpace News: On 12 October 2026, Beijing Luzhu Biotechnology Co., Ltd. (stock code: 02480.HK) announced on a voluntary basis that its recombinant respiratory syncytial virus (RSV) vaccine has been approved by China's National Medical Products Administration for clinical trials in China.
The product is a self-developed recombinant protein vaccine candidate for preventing lower respiratory tract disease (LRTD) caused by RSV; it is a liquid formulation with an aluminium adjuvant that uses the RSV pre-fusion F (Pre-F) protein antigen. RSV is a common respiratory pathogen that can develop into severe conditions such as bronchiolitis and pneumonia in susceptible people, and China currently has no RSV-specific therapeutic drug, with clinical care mainly supportive. The approval lays a foundation for the Group's development of subsequent recombinant protein vaccine candidates.
